Guanosine: A Comprehensive Encyclopedic Reference
1. Identity, Chemistry, and Natural Sources
Chemical Identity
Guanosine (symbol G or Guo) is a purine nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. Its systematic chemical name is 2-amino-9-β-D-ribofuranosyl-9H-purin-6-(1H)-one, with the molecular formula C10H13N5O5 and a molecular weight of 283.24. Guanosine is found in all living organisms as a structural component of RNA, and its chemical formula is C10H13N5O5. Guanosine exhibits maximum UV absorption at 256 nm and is slightly soluble in cold water but soluble in warm water.
Guanosine can be phosphorylated to become guanosine monophosphate (GMP), cyclic guanosine monophosphate (cGMP), guanosine diphosphate (GDP), and guanosine triphosphate (GTP). These forms play important roles in various biochemical processes such as synthesis of nucleic acids and proteins, photosynthesis, muscle contraction, and intracellular signal transduction (cGMP). When guanine is attached by its N9 nitrogen to the C1 carbon of a deoxyribose ring it is known as deoxyguanosine.
Natural Sources
In foods, purines exist as free bases, nucleosides, nucleotides, and nucleic acids in RNA and DNA, with nucleic acids being the predominant form. In the human body, purines are synthesized through the de novo synthetic pathway from the degradation of nucleic acids in live and dying cells. They are also obtained exogenously by consuming foods, beverages, and dietary supplements.
Nucleotides, particularly IMP, are mainly found in protein-rich food ingredients such as organ meats, poultry, and seafood. Yeast protein sources, such as baker's or brewer's yeast and yeast extract, are ingredients that also show a relatively high concentration of nucleotides. Examples of high-purine food sources include anchovies, sardines, liver, beef, kidneys, brains, monkfish, dried mackerel, and shrimp. Guanine itself, the nucleobase component of guanosine, occurs in such diverse natural sources as guano (the accumulated excrement and dead bodies of birds, bats, and seals), sugar beets, yeast, and fish scales. Guanine was first discovered in guano in 1846 and was isolated in 1891 from nucleic acids from which it is readily prepared.
Guanosine also occurs as a significant nucleoside constituent in certain fungi. Nucleosides and their nucleobases are one of the major active components of Cordyceps. Up to now, approximately twenty varieties of nucleosides and their analogues, including cordycepin, adenosine, uridine, guanosine, and inosine, have been found in Cordyceps.
Synthesis and Preparations
Chemical syntheses of adenosine and guanosine were described in 1948; since that time there has been rapid progress in the synthesis of nucleosides and their combination into nucleic acids. Guanosine can be synthesized either by polymerization of a guanine derivative with a D-ribose derivative or by dephosphorylation of guanylic acid. Guanosine hydrate is the hydrated form of guanosine, in which the 9-position of guanine is bonded to the 1-position of D-ribose with an N-glucoside linkage. Commercially, guanosine is available as a white crystalline powder for use in research and as a dietary ingredient. Its phosphorylated derivative GMP (guanosine-5'-monophosphate, typically supplied as the disodium salt) is widely used in food and supplement applications. Saccharomyces cerevisiae and Cyberlindnera jadinii are widely utilized in the natural food seasoning industry as sources of flavor-enhancing nucleotides such as inosine monophosphate (IMP) and guanosine monophosphate (GMP), which contribute to umami taste and support sodium reduction in food.
Flavor and Food Industry Role
IMP and GMP are purine nucleotides that serve as key flavor enhancers, especially in the development of the umami taste, recognized as the fifth basic taste alongside sweet, sour, salty, and bitter. MSG is one of the most well-known umami compounds. When mixed with glutamic acid at a 1:1 ratio, IMP can enhance the umami flavor by approximately sevenfold, while GMP can boost it up to thirtyfold. These nucleotides also contribute to sodium reduction in food products.
2. Historical and Traditional Context
Guanosine does not have a well-documented history of deliberate use as an isolated supplement in traditional medicine systems, as it is a molecular entity that was only characterized through the tools of modern biochemistry and organic chemistry. Guanine was first discovered in guano in 1846 and isolated from nucleic acids in 1891. Chemical syntheses of adenosine and guanosine were first described in 1948. The scientific elucidation of guanosine as a discrete biological compound thus belongs entirely to the era of modern chemistry and biochemistry.
What constitutes guanosine's pre-modern "traditional use" is therefore indirect: foods rich in nucleotides — organ meats, yeast extracts, fermented broths, and seafood — have been consumed across many world cultures for millennia precisely because of their palatability and nutritional density, without any knowledge of their nucleoside content. In foods, purines exist as free bases, nucleosides, nucleotides, and nucleic acids in RNA and DNA, with nucleic acids being the predominant form. In the human body, purines are synthesized through the de novo synthetic pathway from the degradation of nucleic acids in live and dying cells. They are also obtained exogenously by consuming foods, beverages, and dietary supplements.
The use of yeast extracts, fermented meat broths, and purine-rich organ meat preparations in Japanese cuisine (dashi), European consommés, and Chinese medicinal cooking provided dietary guanosine and its relatives as incidental components of culinary tradition. Nucleotides are mainly found in protein-rich food ingredients such as organ meats, poultry, and seafood. Yeast protein sources such as baker's or brewer's yeast and yeast extract also show a relatively high concentration of nucleotides. The explicit supplemental use of isolated guanosine belongs to the late 20th and early 21st centuries, driven by the emerging science of purinergic signaling.
3. Key Constituents, Phosphorylated Derivatives, and Biochemical Context
Guanosine itself is the parent compound, but its pharmacological and physiological significance is inseparable from its broader family of phosphorylated derivatives.
- GMP (Guanosine-5'-monophosphate): The primary mononucleotide form used in food flavoring and as a dietary supplement ingredient. Also an important intermediate in purine metabolism.
- cGMP (Cyclic guanosine monophosphate): A critical intracellular second messenger, particularly in smooth muscle relaxation and phototransduction.
- GDP (Guanosine diphosphate) and GTP (Guanosine triphosphate): These forms play important roles in various biochemical processes such as synthesis of nucleic acids and proteins, photosynthesis, muscle contraction, and intracellular signal transduction.
Purine bases such as adenine and guanine, their corresponding nucleosides such as adenosine and guanosine, and their metabolic products such as the nucleoside inosine and the bases hypoxanthine and xanthine, as well as purine nucleotides including ATP, ADP, AMP, GTP, GDP, and GMP, are ubiquitous molecules found within the cells of animals and plants.
In the context of purine catabolism in humans, guanine nucleotides are hydrolyzed to the nucleoside guanosine, which undergoes phosphorolysis to guanine and ribose-1-phosphate. The conversion of guanosine into uric acid can be catalyzed by guanine deaminase following guanine formation by nucleotidase. The salvage pathway for guanine relies on the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which salvages guanine and hypoxanthine.
Critically, guanosine is not merely a building block but functions as an extracellular signaling molecule. Guanosine, a guanine-based purine, is recognized as an extracellular signaling molecule that is released from astrocytes and confers neuroprotective effects in several in vivo and in vitro studies. Glial cells are involved in multiple cerebral functions that profoundly influence brain tissue viability during ischemia, and astrocytes are the main source of extracellular purines such as adenosine and guanosine.
4. Mechanisms of Action
4.1 Modulation of the Glutamatergic System
One of the most well-characterized mechanisms of extracellular guanosine is its ability to regulate glutamatergic neurotransmission. Previous studies showed that guanosine modulates the glutamate uptake activity, thus avoiding glutamatergic excitotoxicity and protecting neural cells. Evidence suggests that guanine-based purines modulate glutamatergic parameters, such as glutamate uptake by astrocytes and synaptic vesicles, seizures induced by glutamatergic agents, response to ischemia and excitotoxicity, and are able to affect learning, memory and anxiety.
4.2 Adenosinergic Receptor Interactions
Researchers have addressed the protein targets for guanosine action and its interaction with glutamatergic and adenosinergic systems and with calcium-activated potassium channels. Most of guanosine's known effects are abolished by previous incubation or treatment with the selective A1R antagonist DPCPX. In vitro protocols of brain ischemia in hippocampus slices and cortical astrocyte cultures demonstrated that DPCPX abolished the protective effects of guanosine in ROS production, glutamate uptake, and cell viability. The precise nature of whether guanosine acts directly on adenosine receptors or through allosteric modulation remains an area of active investigation; new and exciting avenues for future investigation include characterization of a selective guanosine receptor.
4.3 Intracellular Signaling Pathways
Intracellular mechanisms modulated by guanosine include prevention of oxidative damage, mitochondrial dysfunction, inflammatory burden and modulation of glutamate transport. In neural stem cells, guanosine increases intracellular cAMP, CREB phosphorylation and BDNF mRNA levels. Guanosine promotes neurite outgrowth in cerebellar neurons culture by PKC activation and in PC12 cells by heme-oxygenase (HO-1) induction. In cultured astrocytes, guanosine promotes cellular proliferation and synthesis and release of neurotrophic factors such as FGF-2 and NGF. Guanosine activates cell survival pathways including PI3K/Akt/PKB signaling in different kinds of cells including glia and neuroblastoma cells.
4.4 GTP Repletion and Energy Metabolism
Ischemic injury to the kidney is characterized in part by nucleotide depletion and tubular cell death in the form of necrosis or apoptosis. Researchers linked anoxia-induced apoptosis in renal cell cultures specifically to the depletion of GTP. They therefore hypothesized that enhancing GTP repletion in vivo might protect function by reducing apoptosis in postischemic tubules. Results in both mice and rats show that guanosine selectively repletes renal GTP levels after 1 hour of reperfusion. This early increase in GTP is accompanied by a significant reduction in medullary apoptosis and a remarkable protective effect on GFR.
4.5 Anti-inflammatory and Antioxidant Activity
Guanosine is thought to have neuroprotective properties. It can reduce neuroinflammation, oxidative stress, and excitotoxicity, as well as exerting trophic effects in neuronal and glial cells. In the inflammatory signaling context, guanosine is an extracellular signaling molecule that is released from astrocytes and has been shown to promote central nervous system defenses in several in vivo and in vitro injury models. Guanosine exhibits glioprotective effects in the C6 astroglial cell line by associating the heme oxygenase-1 (HO-1) signaling pathway with protection against azide-induced oxidative stress.
5. Scientific Evidence by Area of Use
5.1 Neuroprotection and Cerebral Ischemia / Stroke
The neuroprotective effects of guanosine in the context of stroke are among the most extensively studied areas in the preclinical literature. Guanosine is a purine nucleoside with important functions in cell metabolism and a protective role in response to degenerative diseases or injury. The past decade has seen major advances in identifying the modulatory role of extracellular action of guanosine in the central nervous system (CNS).
In a key in vitro and in vivo rodent study: deprivation of oxygen and glucose for 5 hours induces apoptosis in SH-SY5Y neuroblastoma cell cultures. After combined glucose and oxygen deprivation, addition of guanosine (100 µM) significantly reduced the proportion of cells undergoing apoptosis. To determine whether guanosine was also neuroprotective in vivo, middle cerebral artery occlusion (MCAo) was performed on male Wistar rats and guanosine (8 mg/kg) administered intraperitoneally, or saline, daily for 7 days. Guanosine prolonged rat survival and decreased both neurological deficits and tissue damage resulting from MCAo. These data were the first to demonstrate that guanosine protects neurons from the effects of combined glucose and oxygen deprivation even when administered 5 hours after the stimulus, and is neuroprotective in experimental stroke in rats.
In a separate rodent focal ischemia study using a thermocoagulation model, guanosine was administered immediately, 1 h, 3 h, and 6 h after surgery. Behavioral performance was evaluated by cylinder testing for 15 days after surgery. GUO treatment was able to restore clinical sensorimotor function, decrease the associated morphological brain damage and abolish the neural cell membrane damage. These results demonstrate an effective neuroprotective role of guanosine against ischemic insult to the brain.
Evidence strength: Substantial and consistent preclinical (rodent) evidence. All studies are animal models or in vitro. As of the available published literature, there are no published large-scale randomized controlled clinical trials in humans evaluating guanosine's efficacy in stroke. Clinical evidence demonstrates that in the majority of stroke patients, slow brain injury evolution is observed in hours-to-days time intervals, which may be caused by reperfusion injury and activation of immunoinflammatory mechanisms. Therefore, a neuroprotective therapy protecting neurons in the penumbra against ischemic and reperfusion injury is still highly demanded.
5.2 Parkinson's Disease
Multiple cell-based studies have examined guanosine in models of Parkinson's disease (PD). Guanosine's protective effects on the central nervous system and on several cell types by inhibiting apoptosis have been shown in a number of pathological conditions. One study analyzed the ability of guanosine to protect neuronal PC12 cells from the toxicity induced by MPP+, the active metabolite of MPTP, which mediates selective damage to dopaminergic neurons and causes irreversible Parkinson-like symptoms in humans and primates. The apoptosis of PC12 cells induced by MPP+ was significantly prevented by pre-treatment for 3 hours with guanosine. Guanosine also attenuated the MPP+-induced collapse of mitochondrial transmembrane potential and prevented the subsequent activation of caspase-3, thereby protecting dopaminergic neurons against mitochondrial stress-induced damage.
In a further in vitro model using 6-OHDA, guanosine (300 µM) protected SH-SY5Y neuroblastoma cells when they were exposed to 6-OHDA, promoting their survival. Guanosine reduced the 6-OHDA-mediated activation of p-38 and JNK. Moreover, the nucleoside potentiated the early increase in the phosphorylation of the anti-apoptotic kinase Akt and the increase in the expression of the anti-apoptotic Bcl-2 protein induced by 6-OHDA. These results showed that guanosine is neuroprotective in a recognized in vitro model of PD, suggesting it could represent a new potential pharmacological tool in the therapeutic approach to PD.
Evidence strength: Preclinical only (cell culture and animal models). No human clinical trials specifically testing guanosine in Parkinson's disease have been identified in the available literature.
5.3 Spinal Cord Injury
Spinal cord injury results in progressive waves of secondary injuries, cascades of noxious pathological mechanisms that substantially exacerbate the primary injury and the resultant permanent functional deficits. Secondary injuries are associated with inflammation, excessive cytokine release, and cell apoptosis. The purine nucleoside guanosine has significant trophic effects and is neuroprotective, antiapoptotic in vitro, and stimulates nerve regeneration. Therefore, researchers determined whether systemic administration of guanosine could protect rats from some of the secondary effects of spinal cord injury, thereby reducing neurological deficits.
Systemic administration of guanosine (8 mg/kg per day, i.p.) for 14 consecutive days, starting 4 h after moderate spinal cord injury in rats, significantly improved not only motor and sensory functions, but also recovery of bladder function. These improvements were associated with reduction in the inflammatory response to injury, reduction of apoptotic cell death, and increased sparing of axons.
An additional rodent study examined chronic SCI and remyelination. Guanosine stimulates proliferation and differentiation of many types of cells in vitro and exerts neuroprotective effects in the CNS. Five weeks after chronic traumatic spinal cord injury, when there is no ongoing recovery of function, intraperitoneal administration of guanosine daily for 2 weeks enhanced functional improvement correlated with the increase in myelination in the injured cord.
Evidence strength: Encouraging but exclusively preclinical (rodent, intraperitoneal administration). No human clinical data are available.
5.4 Depression and Mood Disorders
A substantial body of preclinical research has accumulated on guanosine's antidepressant-like effects. Depressive patients present decreased levels of serum guanosine, an endogenous nucleoside with neuroprotective properties, corroborating the idea that the purinergic signaling is involved in MDD pathophysiology. Innovative studies suggest that the purine cycle and/or the purinergic signaling can be dysregulated in MDD, and the endogenous nucleoside guanosine has gained attention due to its extracellular effects.
The acute administration of guanosine causes an antidepressant-like effect in two predictive animal models: the forced swimming test (FST) and the tail suspension test (TST). These effects are dependent on the activation of the PI3K signaling pathway.
A single i.p. injection of guanosine, or ketamine, completely reversed OBX-induced anhedonic-like behavior 24 or 48 hours post-treatment, as well as short-term recognition memory impairment 48 hours post-treatment.
In a chronic administration study: mice received daily i.p. administration of 7.5 mg/kg GUO or 40 mg/kg imipramine for 45 days. GUO and imipramine reversed the OBX-induced hyperlocomotion and recognition memory impairment, hippocampal BDNF increase, and redox imbalance. GUO also mitigated OBX-induced hippocampal neuroinflammation.
Regarding mechanisms in mood disorders, although guanosine is an endogenous nucleoside that displays antidepressant-like properties in several animal models, the mechanism underlying its antidepressant-like effects is not well characterized. One study investigated the involvement of ERK/GSK-3β and Nrf2/HO-1 signaling pathways in the antidepressant-like effect of guanosine in the mouse tail suspension test.
Evidence strength: Preclinical only. To date, antidepressant-like effects have only been evaluated in predictive animal models, and the elucidation of the mechanisms underlying the antidepressant-like properties of guanosine is still in its early stages. No human clinical trials have been published.
5.5 Pain and Nociception
Evidence from rodent and cell models shows a number of neurotrophic and neuroprotective effects of guanosine, including preventing deleterious consequences of seizures, spinal cord injury, and pain. Several rodent studies have investigated guanosine's antinociceptive properties. Research examining the mechanisms of guanosine-induced antinociception found that pretreatment with non-selective and selective A1/A2A adenosine receptor antagonists significantly affected guanosine-induced nociception. Therefore, at least for antinociception, adenosine receptors seem to be relevant.
Evidence strength: Preclinical (rodent). No human clinical trials have been reported on guanosine for pain management.
5.6 Traumatic Brain Injury
Traumatic brain injury (TBI) is one of the most common types of brain injuries that cause death or persistent neurological disturbances in survivors. Most promising experimental drugs were not effective in clinical trials. Guanosine, an endogenous neuroprotective nucleoside, had not previously been evaluated in TBI. A single dose of guanosine (7.5 mg/kg, intraperitoneally) injected 40 minutes after fluid percussion injury in rats protected against locomotor and exploratory impairments 8 hours after injury.
Evidence strength: Single preclinical study; very early stage.
5.7 Renal Protection and Ischemia
The link between guanosine supplementation and renal protection was investigated in rodent ischemia models. Male C57 black mice underwent bilateral renal artery clamp for 32 minutes to induce ischemia and then received either normal saline or guanosine. After 1 hour of reperfusion, renal GTP levels in the saline/ischemia group were reduced to nearly half of those in sham-operated mice, whereas these levels were nearly unchanged in the guanosine/ischemia group. There was a significant reduction in the number of apoptotic tubular cells in the medulla in the guanosine-treated group compared with the saline group.
Evidence strength: Preclinical (rodent). No human clinical data available.
5.8 Ammonia Neurotoxicity / Hyperammonemia
In rodent models of acute ammonia intoxication, guanosine drastically reduced the lethality rate and the duration of coma. Animals treated with guanosine had improved EEG traces, decreased CSF levels of glutamate and alanine, lowered oxidative stress in the cerebral cortex, and increased glutamate uptake by astrocytes in brain slices compared with animals that received vehicle. This study provides new evidence on mechanisms of guanine-derived purines in their potential modulation of the glutamatergic system, contributing to guanosine neuroprotective effects in a rodent model of acute ammonia intoxication.
Evidence strength: Preclinical (rodent). No human data available.
5.9 Dietary Nucleotides: Immune and Gastrointestinal Systems
While specific clinical research on isolated guanosine supplementation for immune or gastrointestinal purposes in humans is limited, a broader body of literature exists for mixed dietary nucleotide preparations that include GMP as a component. Although endogenous production serves as the main nucleotide source, evidence suggests that exogenous sources are essential to immune competence, intestinal development, and recovery. Dietary nucleotides serve a marked role in rapidly proliferating cells where they are necessary for optimal function. Accordingly, dietary nucleotides are deemed conditionally essential in the presence of various physiological stresses, including growth and development, recovery from injury, infection, and certain disease states.
Under conditions of limited nucleotide intake, rapid growth or certain disease states, dietary nucleotides may spare the cost of de novo nucleotide synthesis and optimize the function of rapidly dividing tissues such as those of the gastrointestinal and immune systems. Animals fed nucleotide-supplemented versus non-supplemented diets have enhanced gastrointestinal growth and maturation, and improved recovery following small and large bowel injury. Indices of humoral and cellular immunity are enhanced, and survival rates are higher following infection with pathogens.
In infant nutrition research: infants receive nucleotides in human milk, where they are present as nucleic acids, nucleosides, nucleotides and related metabolic products. The nucleotide content of human milk is significantly higher than most cow's milk-based infant formulae. Dietary nucleotides are reported to enhance the gastrointestinal and immune systems of formula-fed infants.
A small human randomized controlled trial examined nucleotide supplementation (the mixed-nucleotide product IntestAidIB, containing GMP among other nucleotides) in people with irritable bowel syndrome: dietary nucleotide supplementation has been shown to have important effects on the growth and development of cells with rapid turnover such as those in the immune system and the gastrointestinal tract. Work with infants has shown that the incidence and duration of diarrhoea is lower when nucleotide supplementation is given, and animal work shows that villi height and crypt depth in the intestine is increased as a result of dietary nucleotides. Dietary nucleotides may be semi-essential under conditions of ill-health, poor diet, or stress.
Clinical studies that evaluated nutrition formulations of nucleotides in combination with other specific nutrient substances demonstrated improved clinical outcomes in patients characterized as critically ill, injured, immune suppressed, or with chronic gastrointestinal conditions. However, conclusions regarding specific benefits of nucleotides are limited.
Evidence strength: Moderate evidence for mixed dietary nucleotide preparations in specific clinical contexts (critically ill patients, formula-fed infants), but this evidence applies to multi-nucleotide formulations and cannot be attributed specifically to guanosine or GMP alone. Isolated guanosine/GMP human clinical data are sparse.
6. Body Systems and Health Areas of Association
- Central nervous system: Guanosine has been shown to be protective in central nervous system diseases including ischemic stroke, Alzheimer's disease, Parkinson's disease, spinal cord injury, nociception, and depression.
- Cardiovascular / vascular system: Via cGMP signaling, guanosine's phosphorylated form participates in smooth muscle relaxation and vascular tone regulation.
- Renal system: GTP depletion is implicated in ischemic tubular injury; guanosine supplementation has been shown to repletion renal GTP and reduce apoptosis in rodent ischemia models.
- Immune system: As a component of dietary nucleotide mixtures, GMP-containing preparations are associated with enhanced immune responsiveness and intestinal immune maturation, especially in rapidly developing or stressed organisms.
- Gastrointestinal system: Dietary nucleotides including GMP are conditionally essential for intestinal epithelial cell proliferation, mucosal integrity, and gut maturation.
- Energy metabolism: GTP, derived from purine nucleotides, is a key energy carrier in cells, facilitating biochemical reactions and cellular processes.
- Genetic information processing: Guanosine triphosphate (GTP) is one of the building blocks of RNA synthesis, and guanosine is found in all living organisms as a structural component of RNA.
7. Dosage Forms and Dosages Reported in Studies
No universally agreed-upon human supplemental dosage exists for isolated guanosine. The following are dosages reported in the cited scientific literature only:
- Rodent neuroprotection/stroke studies: Guanosine 8 mg/kg intraperitoneally, daily for 7 days, in MCAo rats.
- Rodent spinal cord injury: Guanosine 8 mg/kg per day intraperitoneally for 14 consecutive days, starting 4 hours after moderate spinal cord injury in rats, significantly improved motor, sensory, and bladder functions.
- Rodent depression models (chronic): Mice received daily i.p. administration of 7.5 mg/kg GUO for 45 days.
- Rodent TBI study: A single dose of guanosine 7.5 mg/kg intraperitoneally, injected 40 minutes after fluid percussion injury in rats, protected against locomotor and exploratory impairments 8 hours after injury.
- In vitro neuroprotection: Addition of guanosine at 100 µM significantly reduced apoptosis in SH-SY5Y neuroblastoma cells subjected to combined glucose and oxygen deprivation.
- In vitro Parkinson's model: Guanosine at 300 µM protected SH-SY5Y neuroblastoma cells from 6-OHDA toxicity.
- Aquaculture / animal nutrition (GMP as dietary supplement): Sea cucumber were fed diets supplemented with graded levels of guanosine from GMP at 0, 0.3, 0.6, and 1.2 g/kg for 8 weeks.
- Oral mouse antidepressant study: Mice were treated with guanosine at 0.05 mg/kg orally, and the Nrf2 immunocontent was analyzed in the hippocampus and prefrontal cortex by Western blotting.
All animal studies were conducted using parenteral (intraperitoneal) or oral administration in rodents. There are currently no established or recommended human oral supplemental doses derived from completed clinical trials.
8. Safety Considerations and Interactions
8.1 Uric Acid and Gout Risk
Because guanosine is a purine nucleoside, its catabolism in humans produces uric acid. This is the central safety consideration for guanosine supplementation in humans at pharmacological doses. Adenine, guanine, hypoxanthine, xanthine, AMP, GMP, and IMP were given in single oral doses at 0.1 mmoles/kg body weight to normouricemic, hyperuricemic and gouty humans, and serum and urinary uric acid levels were monitored. Oral hypoxanthine, AMP, GMP, IMP and adenine elevated serum uric acid levels while guanine and xanthine did not affect serum uric acid. Hypoxanthine, AMP, GMP, and IMP produced a greater hyperuricemic effect on subjects with gout compared with hyperuricemic and normouricemic controls.
This is an important distinction: the free nucleobase guanine did not raise uric acid, whereas GMP (guanosine-5'-monophosphate), the most commonly supplemented form, did. Hypoxanthine, IMP, adenine, AMP, and GMP were found to increase the serum concentration of uric acid in normal and hyperuricemic subjects and those with gout. Interestingly, guanine itself has not been reported to change serum level or urinary excretion of uric acid.
The link between purines and gout stems from the fact that purine breakdown leads to production of urate, though in the majority of individuals this process does not lead to hyperuricemia. Several enzymatic reactions lead to the conversion of purines into uric acid. When purine overload in the body exceeds the body's ability to manage it, excessive uric acid can accumulate in the bloodstream. This condition, presenting with an elevated serum uric acid concentration, is known as hyperuricemia, and gout induced by hyperuricemia is deemed to be the metabolic disease linked to purines.
8.2 Urolithiasis
Elevated uric acid levels from purine supplementation carry a risk of kidney stone formation. Based on closely related purine nucleoside research (inosine, a metabolic neighbor of guanosine): potential side effects of purine nucleoside supplementation relate to the resulting elevated urate (uric acid) levels (hyperuricemia). Hyperuricemia has been linked to gout (which generally develops in people with serum urate concentrations above 8 mg/dL) and to the formation of urate stones in the kidneys or ureters (urolithiasis). In most uric acid stone formers the primary pathophysiologic defect is an excessively acidic urine pH rather than hyperuricemia alone.
8.3 Purine Nucleoside Phosphorylase (PNP) Deficiency
Guanosine is found to be associated with purine nucleoside phosphorylase (PNP) deficiency, which is an inborn error of metabolism. Individuals with PNP deficiency are unable to normally catabolize guanosine and related nucleosides, leading to their accumulation, which has severe immunological consequences. Such individuals would be at particular risk from guanosine supplementation.
8.4 Potential Drug-Nucleoside Interactions
Abacavir, a drug used in the treatment of HIV/AIDS, is an analog of guanosine, possessing a purine nucleoside consisting of guanine attached to a ribose molecule; abacavir is classified specifically as a nucleoside reverse transcriptase inhibitor. Various other nucleoside analogs exist; some are used to treat cancer or rheumatic diseases, while others act against bacterial or viral infections. The theoretical possibility exists that high-dose exogenous guanosine supplementation could compete with nucleoside drug analogs at nucleoside transporters or phosphorylating enzymes, potentially altering their bioavailability or activity, though this has not been systematically studied in the context of dietary supplementation.
8.5 Intestinal Absorption and Metabolism
Differences in the efficiency of uptake among nucleosides have been reported, with guanosine being taken up most rapidly. More than 90% of dietary and endogenous nucleosides and bases are transported into the enterocytes. Nucleoside transport into the enterocyte occurs by facilitated diffusion and by specific Na+-dependent carrier-mediated mechanisms. Several enterocyte degradation products of dietary and endogenous nucleotides and nucleosides, mainly nitrogenous bases such as adenine, cytosine, guanine, hypoxanthine, uracil, or thymine, enter the hepatic portal vein. These molecules are carried to the hepatocytes for further metabolism; thereafter, they are released from the liver into systemic circulation and enter muscle tissue.
8.6 General Safety Profile
Guanosine and its derivatives are endogenous molecules present in all human cells. At dietary exposure levels through food, they are not associated with toxicity. At pharmacologically amplified supplemental doses, the principal documented risk is elevation of serum uric acid, relevant particularly to individuals with pre-existing hyperuricemia, gout, or kidney disease. In healthy people, dietary nucleotides are probably not essential, and in fact most will be metabolised and rapidly excreted from the system. However, under certain circumstances (e.g., in the sub-well, diseased, or under conditions of stress or poor diet) dietary nucleotides may be "semi-essential", optimising the function of the gastrointestinal and immune systems. No formal toxicological dose-finding or safety evaluation of isolated guanosine in human supplement use has been reported in the published peer-reviewed literature.
References
Go back